ReviewBioMed research international2025
Current Progress of Cell Therapy Clinical Trials in China in 2014-2024.
Review in BioMed research international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Progress of Cell Therapy Clinical Trials in China in 2014-2024.BioMed research international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This paper summarizes the cell therapy clinical trials in China over the past decade to put forward suggestions for future clinical development in this field. Methods: Mainly based on the Centre for Drug Evaluation of China National Medical Products Administration (NMPA) website, a list and detailed information of cell therapy drugs in China were acquired. The annual number and basic characteristics including cell type, clinical trial phase, clinical trial status, geographical distribution, disease types, and drug target of registered drugs were summarized. Results: There have been 206 cell therapy trials between 2014 and 2024 in China. The top three cell types are T cells (51.4%, 106/206), stem cells (34.0%, 70/206), and progenitor cells (4.9%, 10/206), respectively. In terms of the phase distribution, 64.1% (132/206) were Phase I, 32.5% (67/206) were Phase II, and 3.4% (7/206) were Phase III. Currently, 86.4% (178/206) of cell therapy trials are open, 9.7% (20/206) have been completed, and the remainder are either suspended or terminated. Geographical analysis showed that 31.6% (65/206) of trials were conducted in Shanghai, 20.4% (42/206) in Beijing, and 9.2% (19/206) in Jiangsu. Twenty-eight disease types were identified, of which lymphoma (15.5%, 32/206) was the top disease type, followed by leukemia (12.6%, 26/206) and inflammation (9.2%, 19/206). The three most common targets were CD19 (54.9%, 39/71), BCMA (9.9%, 7/71), and EGFR (5.6%, 4/71). Conclusions: Cell therapy clinical trials in China have developed rapidly in the past decade. Perhaps in the future, the direction worthy of attention could include increasing funding for Phase III clinical trials, supporting a more balanced geographical distribution of trials, and more investment in target development. With the continuous progress of technology, cell therapy is expected to become an important means to treat various diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.